- Poster presentation
- Open Access
Pharmacokinetics of long-lasting, high-dose dexmedetomidine infusions in critically ill patients
© Iirola et al. 2011
- Published: 1 March 2011
- Infusion Rate
- Intensive Care Patient
The aim of this study was to characterize the pharmaco-kinetics of long dexmedetomidine (dexmed) infusions and assess the dose linearity of high doses.
Dexmed was infused to critically ill intensive care patients for 12 hours using a constant infusion rate determined by the prestudy dose of propofol or midazolam. After the first 12 hours, the infusion rate of dexmed was titrated between 0.1 and 2.5 μg/kg/hour using prefixed levels to maintain sedation in range of 0 to -3 on the Richmond Agitation-Sedation Scale (RASS). Dexmed was continued as long as required to a maximum of 14 days. Safety and tolerability were assessed by adverse events, heart rate, blood pressure, ECG and laboratory tests.
The pharmacokinetics of dexmed was linear up to the dose of 2.5 μg/kg/hour. Despite the high dose and long-lasting infusions, safety findings were as expected for dexmed and the patient population.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.